Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25363762 | 1.00 | MEN1 (0.37) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL25362157 | 1.00 | MEN1 (0.37) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL25364457 | 0.93 | MEN1 (0.37) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL27034331 | 0.92 | MEN1 (0.35) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL27034307 | 0.92 | MEN1 (0.35) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL27034456 | 0.92 | MEN1 (0.35) | MEN1KMT2ATACR2HPGDPOLB | |
| SCHEMBL25365546 | 0.89 | MEN1 (0.35) | MEN1KMT2ATACR2HPGDHSD11B1 | |
| SCHEMBL25363425 | 0.88 | IRAK4 (0.33) | MEN1KMT2A | |
| SCHEMBL25363575 | 0.88 | IRAK4 (0.33) | MEN1KMT2A | |
| SCHEMBL25365553 | 0.88 | IRAK4 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | claimed |
| CN-119731156-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119731156-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | MEN1 4008/4885KMT2A 4010/4885TACR2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.